Becton Dickinson & (BDX) stock
Last close $212.68 on 2026-11-19 (-1.57%) · Sector: Healthcare
Becton, Dickinson and Company is a global medical technology company that makes medical supplies, devices, and lab tools used by hospitals, labs, and pharmacies. It earns money mainly by selling these products worldwide, with the company's revenue of about $22.4 billion over the last twelve months coming from that business.
BDX's business is growing, with revenue up 13.1% over the past year, though profits have been uneven from quarter to quarter. Over the past year the stock returned 12.2%, which beat the S&P 500's 9.7% return, and it trades about 3.5% below its 52-week high. Insiders sold $0.7 million of stock in the last 90 days and made no purchases, and the stock has usually risen the day after earnings reports.
Key numbers
- Market cap: $58.5B
- Revenue (last 12 months): $22.41B
- Revenue growth: +13.1%
- Gross margin: 46.5%
- Operating margin: 10.3%
- P/E: 64.3
- P/S: 2.6
- Debt to equity: 0.55
- Current ratio: 0.87
Quality score
Overall 29/100 · growth 40 · profitability 32 · financial health 45 · value 0
Performance and risk
1-year return +12.2% vs S&P 500 +9.7% · volatility 31.2% (S&P 500 13.8%) · largest drop -33.0% · beta 0.31
Stock move the day after earnings
- 2026-02-09: -1.3%
- 2026-04-02: +0.5%
- 2026-05-07: +5.9%
- 2026-08-06: +3.8%
- 2026-11-05: +2.1%
Insider trades (12 months)
Bought $0.0M · sold $3.2M
BDX stock research · BDX options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.